Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Ascending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J0885 Epoetin Alfa Epogen, Procrit 1000 units Ancillary Therapy Erythropoiesis-Stimulating Agent No 1989 Jan. 1, 2006 In Use
J1436 Etidronate Disodium Didronel 300 mg Ancillary Therapy Bisphosphonate No 1977 Jan. 1, 1990 In Use
J3487 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2003 Dec. 31, 2013 No Longer Used
J3489 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2014 In Use
Q2051 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 July 1, 2013 Jan. 1, 2014 No Longer Used
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 July 1, 2020 In Use
NA Cysteamine Bitartrate Cystagon 50mg, 150mg Chemotherapy Cystine-Depleting Agent Yes 1994 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use

Found 716 results in 1 millisecond — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.